Kura Oncology, Inc.

DB:KUR Stock Report

Market Cap: €478.9m

Kura Oncology Management

Management criteria checks 2/4

Kura Oncology's CEO is Troy Wilson, appointed in Mar 2015, has a tenure of 10.17 years. total yearly compensation is $6.24M, comprised of 10.8% salary and 89.2% bonuses, including company stock and options. directly owns 0.67% of the company’s shares, worth €3.11M. The average tenure of the management team and the board of directors is 3.4 years and 9.6 years respectively.

Key information

Troy Wilson

Chief executive officer

US$6.2m

Total compensation

CEO salary percentage10.77%
CEO tenure10.2yrs
CEO ownership0.7%
Management average tenure3.4yrs
Board average tenure9.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Troy Wilson's remuneration changed compared to Kura Oncology's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

-US$182m

Dec 31 2024US$6mUS$672k

-US$174m

Sep 30 2024n/an/a

-US$198m

Jun 30 2024n/an/a

-US$182m

Mar 31 2024n/an/a

-US$168m

Dec 31 2023US$5mUS$646k

-US$153m

Sep 30 2023n/an/a

-US$143m

Jun 30 2023n/an/a

-US$140m

Mar 31 2023n/an/a

-US$137m

Dec 31 2022US$5mUS$621k

-US$136m

Sep 30 2022n/an/a

-US$135m

Jun 30 2022n/an/a

-US$133m

Mar 31 2022n/an/a

-US$132m

Dec 31 2021US$9mUS$600k

-US$130m

Sep 30 2021n/an/a

-US$124m

Jun 30 2021n/an/a

-US$114m

Mar 31 2021n/an/a

-US$101m

Dec 31 2020US$4mUS$573k

-US$90m

Sep 30 2020n/an/a

-US$81m

Jun 30 2020n/an/a

-US$74m

Mar 31 2020n/an/a

-US$68m

Dec 31 2019US$3mUS$542k

-US$63m

Sep 30 2019n/an/a

-US$61m

Jun 30 2019n/an/a

-US$60m

Mar 31 2019n/an/a

-US$60m

Dec 31 2018US$5mUS$526k

-US$60m

Compensation vs Market: Troy's total compensation ($USD6.24M) is above average for companies of similar size in the German market ($USD917.60K).

Compensation vs Earnings: Troy's compensation has increased whilst the company is unprofitable.

CEO

Troy Wilson (55 yo)

10.2yrs
Tenure
US$6,239,098
Compensation

Dr. Troy Edward Wilson, Ph D., J.D., serves as Independent Director and Chairman of the Board of Montara Therapeutics, Inc. since March 2025. He is Independent Director of Cartography Biosciences, Inc. fro...

Leadership Team

NamePositionTenureCompensationOwnership
Troy Wilson
Chairman10.2yrsUS$6.24m0.67%
€ 3.2m
Kathleen Ford
Chief Operating Officer5.8yrsUS$2.50m0.018%
€ 87.9k
Teresa Bair
Chief Legal Officer & Corporate Secretary3.6yrsUS$2.27m0.018%
€ 85.4k
Thomas Doyle
Senior Vice President of Finance & Accounting3.3yrsno data0.024%
€ 117.2k
Francis Burrows
Chief Scientific Officerless than a yearno data0.020%
€ 97.3k
Roger Bakale
Senior Vice President of Manufacturing & Supply Chain5.3yrsno datano data
Maureen Clancy
VP and Global Head of Program Leadership & Project Management4.2yrsno datano data
Mollie Leoni
Chief Medical Officer3.3yrsno data0.016%
€ 78.5k
Brian Powl
Chief Commercial Officer1.8yrsno datano data
Samir Vattompadam
Senior Vice President of Global Program Leadershipless than a yearno datano data
3.4yrs
Average Tenure
53yo
Average Age

Experienced Management: KUR's management team is considered experienced (3.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Troy Wilson
Chairman10.2yrsUS$6.24m0.67%
€ 3.2m
Daniel Von Hoff
Clinical Advisorno datano datano data
Thomas Malley
Independent Director9.6yrsUS$401.07k0%
€ 0
Mary Szela
Independent Director6.5yrsUS$406.07k0%
€ 0
Faheem Hasnain
Lead Independent Director10.1yrsUS$426.07k0.028%
€ 132.7k
Frank McCormick
Scientific Advisorno datano datano data
Neal Rosen
Scientific Advisorno datano datano data
Kevan Shokat
Chairman of the Scientific Advisory Boardno datano datano data
Alan Houghton
Clinical Advisorno datano datano data
Josep Tabernero
Clinical Advisorno datano datano data
Steven Horwitz
Clinical Advisorno datano datano data
Carol Schafer
Independent Director3.9yrsUS$406.07k0%
€ 0
9.6yrs
Average Tenure
63yo
Average Age

Experienced Board: KUR's board of directors are considered experienced (9.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/20 23:19
End of Day Share Price 2025/05/20 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kura Oncology, Inc. is covered by 20 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Peter LawsonBarclays
Jason ZemanskyBofA Global Research
Leah Rush CannBrookline Capital Markets